argenx SE (BSP:A1RG34) Total Tax Payable: R$251 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:A1RG34 argenx SE BSP:A1RG34
81 GF Score
Price R$213.15
GF Value R$299.51
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Total Tax Payable?

argenx SE BSP:A1RG34 81 Total Tax Payable is R$251 Mil as of Jun. 2026. GuruFocus rates BSP:A1RG34 with a GF Score™ of 81/100 and a GF Value™ of R$299.51 (Modestly Undervalued). The stock has 5 warning signs investors should review.

argenx SE's Total Tax Payable for the quarter that ended in Jun. 2026 was R$251 Mil.

argenx SE's quarterly Total Tax Payable declined from Dec. 2025 (R$230 Mil) to Mar. 2026 (R$0 Mil) but then increased from Mar. 2026 (R$0 Mil) to Jun. 2026 (R$251 Mil).

argenx SE's annual Total Tax Payable increased from Dec. 2023 (R$21 Mil) to Dec. 2024 (R$82 Mil) and increased from Dec. 2024 (R$82 Mil) to Dec. 2025 (R$230 Mil).

argenx SE Total Tax Payable Historical Data

* Premium members only.

The historical data trend for argenx SE's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Total Tax Payable Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.40 16.69 21.24 81.69 230.28

argenx SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.71 0.00 230.28 0.00 251.08
BSP:A1RG34
81GF Score
argenx SE BSP:A1RG34
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of R$251 Mil mean?
argenx SE (BSP:A1RG34) has a Total Tax Payable of R$251 Mil as of Jun. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on argenx SE and its competitors.
Is argenx SE's Total Tax Payable too high?
argenx SE's current Total Tax Payable is R$251 Mil. Overall, argenx SE has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Total Tax Payable compare to VRTX and REGN?
argenx SE's Total Tax Payable of R$251 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on argenx SE and its competitors. argenx SE's current Total Tax Payable is R$251 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (BSP:A1RG34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$299.51, compared to a current price of R$213.15 — trading 28.8% below its estimated fair value. The current Total Tax Payable is R$251 Mil. argenx SE's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For argenx SE (BSP:A1RG34), the current Total Tax Payable is R$251 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (BSP:A1RG34) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of R$213.15 is trading 28.8% below its estimated GF Value™ of R$299.51. GuruFocus considers argenx SE to be Modestly Undervalued.

Key valuation signals for BSP:A1RG34:

  • Total Tax Payable: R$251 Mil
  • GF Value™: R$299.51 vs. price of R$213.15 (28.8% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the BSP:A1RG34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
81GF Score

Get the complete analysis for BSP:A1RG34

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$213.15
Price
R$299.51
GF Value